Clinical Trial Update: Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating enavogliflozin for functional tricuspid regurgitation in patients with heart failure with preserved ejection fraction is active but not…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction
• Tricuspid Regurgitation

Drugs mentioned

• Enavogliflozin (enavogliflozin)

Snippet

Sponsor: Asan Medical Center | Conditions: Tricuspid Regurgitation, Heart Failure With Preserved Ejection Fraction | Phase 3 | Status: ACTIVE_NOT_RECRUITING